• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Actual growth rate and tumour cell proliferation in human pulmonary neoplasms.人类肺部肿瘤的实际生长速率与肿瘤细胞增殖
Br J Cancer. 1984 Sep;50(3):343-9. doi: 10.1038/bjc.1984.181.
2
A comparison of patient survival and tumour growth kinetics in human bronchogenic carcinoma.人类支气管源性癌患者生存率与肿瘤生长动力学的比较。
Br J Cancer. 1988 Oct;58(4):419-22. doi: 10.1038/bjc.1988.233.
3
Cell proliferation and histologic classification of bronchogenic carcinoma.支气管源性癌的细胞增殖与组织学分类
J Natl Cancer Inst. 1977 Oct;59(4):1113-8. doi: 10.1093/jnci/59.4.1113.
4
In vitro thymidine labelling of human pulmonary neoplasms.人肺肿瘤的体外胸苷标记
Br J Cancer. 1983 Feb;47(2):245-52. doi: 10.1038/bjc.1983.32.
5
c-myc oncoprotein in bronchial carcinoma: expression in all major morphological types.支气管癌中的c-myc癌蛋白:在所有主要形态学类型中的表达
Anticancer Res. 1990 May-Jun;10(3):623-8.
6
Tumor doubling time and survival of men with bronchogenic carcinoma.支气管源性癌男性患者的肿瘤倍增时间与生存率
Chest. 1974 Jan;65(1):3-8. doi: 10.1378/chest.65.1.3.
7
Bronchogenic carcinoma: radiologic-pathologic correlation.支气管源性癌:放射学与病理学的相关性
Radiographics. 1994 Mar;14(2):429-46; quiz 447-8. doi: 10.1148/radiographics.14.2.8190965.
8
Tumour volume and macroscopic growth pattern of bronchogenic carcinoma.支气管源性癌的肿瘤体积和大体生长模式。
Virchows Arch A Pathol Anat Histopathol. 1985;405(3):387-97. doi: 10.1007/BF00710073.
9
Bronchogenic carcinoma. A study of 109 cases.支气管源性癌。109例病例研究。
J Assoc Physicians India. 1989 Jun;37(6):379-82.
10
Bronchogenic carcinoma--a clinico-pathological study.支气管源性癌——一项临床病理研究。
Indian J Chest Dis. 1972 Apr;14(2):78-85.

引用本文的文献

1
Breaking barriers: harnessing hypofractionated radiotherapy to transform outcomes in low tumor mutation burden stage III non-small cell lung cancer - a retrospective study.突破障碍:利用大分割放疗改善低肿瘤突变负荷Ⅲ期非小细胞肺癌的治疗结局——一项回顾性研究
Front Immunol. 2025 Apr 9;16:1557154. doi: 10.3389/fimmu.2025.1557154. eCollection 2025.
2
Hijacking homeostasis: Regulation of the tumor microenvironment by apoptosis.劫持内稳态:细胞凋亡对肿瘤微环境的调控。
Immunol Rev. 2023 Oct;319(1):100-127. doi: 10.1111/imr.13259. Epub 2023 Aug 8.
3
How translational modeling in oncology needs to get the mechanism just right.肿瘤学中的转化模型需要恰到好处地把握机制。
Clin Transl Sci. 2022 Mar;15(3):588-600. doi: 10.1111/cts.13183. Epub 2021 Nov 12.
4
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions.广泛期小细胞肺癌的一线免疫检查点抑制剂:临床进展和未来方向。
ESMO Open. 2021 Feb;6(1):100003. doi: 10.1016/j.esmoop.2020.100003. Epub 2021 Jan 13.
5
Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy.周转率调节适应性治疗中抵抗成本的需求。
Cancer Res. 2021 Feb 15;81(4):1135-1147. doi: 10.1158/0008-5472.CAN-20-0806. Epub 2020 Nov 10.
6
Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review.局部晚期 NSCLC 采用改良分割方案进行放射剂量递增:系统评价。
Thorac Cancer. 2020 Jun;11(6):1375-1385. doi: 10.1111/1759-7714.13451. Epub 2020 Apr 22.
7
Cancer recurrence times from a branching process model.从分支过程模型看癌症复发次数。
PLoS Comput Biol. 2019 Nov 21;15(11):e1007423. doi: 10.1371/journal.pcbi.1007423. eCollection 2019 Nov.
8
The impact of proliferation-migration tradeoffs on phenotypic evolution in cancer.增殖-迁移权衡对癌症表型进化的影响。
Sci Rep. 2019 Feb 20;9(1):2425. doi: 10.1038/s41598-019-39636-x.
9
Spontaneous death of rat chloroleukaemia cells induced by an endogenous growth inhibitor.内源性生长抑制剂诱导大鼠氯白血病细胞的自然死亡
Cell Prolif. 2018 Feb;51(1). doi: 10.1111/cpr.12421. Epub 2017 Dec 10.
10
Increased Biological Effective Dose of Radiation Correlates with Prolonged Survival of Patients with Limited-Stage Small Cell Lung Cancer: A Systematic Review.放疗生物有效剂量增加与局限期小细胞肺癌患者生存期延长相关:一项系统评价
PLoS One. 2016 May 26;11(5):e0156494. doi: 10.1371/journal.pone.0156494. eCollection 2016.

本文引用的文献

1
RATES OF GROWTH OF PULMONARY METASTASES AND HOST SURVIVAL.肺转移瘤的生长速率与宿主生存率
Ann Surg. 1964 Feb;159(2):161-71. doi: 10.1097/00000658-196402000-00001.
2
The frequency distribution of the rates of growth and the estimated duration of primary pulmonary carcinomas.原发性肺癌的生长速率频率分布及估计病程
Cancer. 1963 Jun;16:687-93. doi: 10.1002/1097-0142(196306)16:6<687::aid-cncr2820160602>3.0.co;2-e.
3
The rate of growth and apparent duration of untreated primary bronchial carcinoma.未经治疗的原发性支气管癌的生长速度和表观病程。
Cancer. 1963 Jun;16:694-707. doi: 10.1002/1097-0142(196306)16:6<694::aid-cncr2820160603>3.0.co;2-j.
4
Observations on growth rates of human tumors.关于人类肿瘤生长速率的观察
Am J Roentgenol Radium Ther Nucl Med. 1956 Nov;76(5):988-1000.
5
In vitro thymidine labelling of human pulmonary neoplasms.人肺肿瘤的体外胸苷标记
Br J Cancer. 1983 Feb;47(2):245-52. doi: 10.1038/bjc.1983.32.
6
Cell loss as a factor in the growth rate of human tumours.细胞丢失作为人类肿瘤生长速率的一个因素。
Eur J Cancer (1965). 1967 Nov;3(4):381-7. doi: 10.1016/0014-2964(67)90022-9.
7
Kinetics of cell proliferation of an experimental tumor.实验性肿瘤的细胞增殖动力学
Cancer Res. 1967 Jun;27(6):1122-31.
8
Growth rate in the detection and prognosis of bronchogenic carcinoma.支气管源性癌的检测与预后中的增长率。
JAMA. 1966 Dec 19;198(12):1246-52.
9
Case for using only maximum diameter in measuring tumors.仅使用最大直径测量肿瘤的理由。
Cancer Chemother Rep. 1966 Mar;50(3):119-24.
10
Tumour growth and anti-mitotic action. The role of spontaneous cell losses.肿瘤生长与抗有丝分裂作用。自发细胞丢失的作用。
Br J Cancer. 1968 Dec;22(4):698-713. doi: 10.1038/bjc.1968.83.

人类肺部肿瘤的实际生长速率与肿瘤细胞增殖

Actual growth rate and tumour cell proliferation in human pulmonary neoplasms.

作者信息

Kerr K M, Lamb D

出版信息

Br J Cancer. 1984 Sep;50(3):343-9. doi: 10.1038/bjc.1984.181.

DOI:10.1038/bjc.1984.181
PMID:6087867
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1976798/
Abstract

Measurement of the Doubling Times [DT] for 27 human pulmonary neoplasms have been made. Squamous and large cell tumours had a wide range of values for DT whereas for small cell undifferentiated carcinoma, and possibly large cell undifferentiated carcinomata without stratification, the range was narrower. Mean DT for different primary bronchogenic carcinoma groups were: Squamous cell 146 days, Adenocarcinoma 72 days, Small cell 66 days, and Large Cell 111 days. The number of adenocarcinomata is very small in number and our value of 72 days is probably not representative of this group of tumours. Relationship between DT and tumour differentiation was difficult to identify in our series. Of these 27 a unique series of 17 have parallel data on DT and Potential Doubling Time (DTpot) and the Cell Loss Factor [0] calculated. Great discrepancy between DT and DTpot existed in each case and cell loss was high, ranging from 54% to 99%. All primary bronchogenic carcinomata had cell loss of greater than 70%; in almost two thirds of these cases the value was 90% or more. All undifferentiated tumours and a majority of poorly differentiated tumours had cell loss of 90% or more. As cell loss increased, tumour thymidine labelling index (TLI) increased and the tumours tended to be less well differentiated. The relationship, if any, between cell loss and DT was unclear.

摘要

已对27例人类肺肿瘤的倍增时间(DT)进行了测量。鳞状细胞癌和大细胞肿瘤的DT值范围较宽,而小细胞未分化癌以及可能未分层的大细胞未分化癌的范围较窄。不同原发性支气管癌组的平均DT为:鳞状细胞癌146天,腺癌72天,小细胞癌66天,大细胞癌111天。腺癌的数量非常少,我们72天的值可能不代表这组肿瘤。在我们的系列研究中,难以确定DT与肿瘤分化之间的关系。在这27例中,有17例有关于DT、潜在倍增时间(DTpot)和计算出的细胞丢失因子(0)的平行数据。在每种情况下,DT与DTpot之间都存在很大差异,细胞丢失率很高,范围从54%到99%。所有原发性支气管癌的细胞丢失率均大于70%;在几乎三分之二的病例中,该值为90%或更高。所有未分化肿瘤和大多数低分化肿瘤的细胞丢失率为90%或更高。随着细胞丢失增加,肿瘤胸腺嘧啶核苷标记指数(TLI)增加,肿瘤分化程度往往较低。细胞丢失与DT之间的关系(如果有的话)尚不清楚。